Parmax Pharma Limited
Bombay Stock ExchangeTotal Valuation
Parmax Pharma Limited carries a market capitalization of 316.25M, placing it among publicly traded companies globally. Its enterprise value stands at 215.09M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 316.25M |
| Enterprise Value | 215.09M |
Share Statistics
Parmax Pharma Limited currently has 3.74M shares outstanding.
| Shares Outstanding | 3.74M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.88, and the price-to-book ratio stands at 2.39.
| PE Ratio | N/A |
| PS Ratio | 0.88 |
| PB Ratio | 2.39 |
| P/TBV Ratio | -1.73 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 1.78 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 23.41 |
Financial Position
Parmax Pharma Limited maintains a current ratio of 0.74, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -187.36, indicating conservative leverage, while an interest coverage ratio of -3.56 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.74 |
| Quick Ratio | 0.03 |
| Debt / Equity | -187.36 |
| Debt / EBITDA | -2.50 |
| Interest Coverage | -3.56 |
Financial Efficiency
| Return on Equity (ROE) | -106.31 |
| Return on Assets (ROA) | -17.77 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.77 |
Taxes
| Income Tax | -16.87M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Parmax Pharma Limited's stock has gained approximately 119.27367% over the past 52 weeks. The 50-day moving average sits at 48.43, while the 200-day moving average is 36.26.
| Beta (5Y) | N/A |
| 52-Week Price Change | 119.27367% |
| 50-Day Moving Average | 48.43 |
| 200-Day Moving Average | 36.26 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Parmax Pharma Limited generated 121.12M in revenue and converted that into -41.59M in net income, yielding earnings per share of -11.12. EBITDA reached -46.01M, while operating income came in at -46.01M.
| Revenue | 121.12M |
| Gross Profit | 22.31M |
| Operating Income | -46.01M |
| Pretax Income | -58.46M |
| Net Income | -41.59M |
| EBITDA | -46.01M |
| EBIT | -46.01M |
| Earnings Per Share (EPS) | -11.12 |
Balance Sheet
Parmax Pharma Limited holds 6.50M in cash and equivalents against 115.18M in total debt, resulting in a net debt position of 108.69M. Total book value stands at 44.51M, with working capital of -60.05M providing operational flexibility.
| Cash & Cash Equivalents | 6.50M |
| Total Debt | 115.18M |
| Net Debt | 108.69M |
| Equity (Book Value) | 44.51M |
| Book Value Per Share | 11.90 |
| Working Capital | -60.05M |
Margins
Parmax Pharma Limited operates with a gross margin of 18.42, reflecting its pricing power and cost economics. The operating margin of -37.99 and net profit margin of -34.34 provide insight into operational efficiency.
| Gross Margin | 18.42 |
| Operating Margin | -37.99 |
| Pretax Margin | -48.27 |
| Profit Margin | -34.34 |
| EBITDA Margin | -37.99 |
Scores
Parmax Pharma Limited posts an Altman Z-Score of -0.18, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -0.18 |